Do Perceptions of Risk and Quality of Life Affect Use of Hormone Replacement Therapy by Postmenopausal Women?

References

1. ↵
   Hormone replacement therapy. ACOG educational bulletin 247. Washington, DC: American College of Obstetricians and Gynecologists, 1998: 1–10.
2. ↵
   Age charts for periodic health examinations (reprint no. 510). Kansas City, Mo: American Academy of Family Physicians, 1994.
3. ↵
   Guidelines for counseling postmenopausal women about preventive hormone therapy. American College of Physicians. Ann Intern Med 1992; 117: 1038–41.
4. ↵
   US Preventive Services Task Force. Guide to clinical preventive services. Baltimore: Lippincott Williams & Wilkins, 1995.
5. ↵
   Keating NL, Cleary PD, Rossi AS, Zaslavsky AM, Ayanian JZ. Use of hormone replacement therapy by postmenopausal women in the United States. Ann Intern Med 1999; 130: 545–53.

   OpenUrlPubMedWeb of Science
6. ↵
   Daley J. Medical uncertainty and practice variation get personal: what should I do about hormone replacement therapy? Ann Intern Med 1999; 130: 602–4.

   OpenUrlPubMedWeb of Science
7. ↵
   Collins A, Landgren BM. Psychosocial factors associated with the use of hormonal replacement therapy in a longitudinal follow-up of Swedish women. Maturitas 1997; 28: 1–9.

   OpenUrlCrossRefPubMedWeb of Science
8. ↵
   Ferguson KJ, Hoegh C, Johnson S. Estrogen replacement therapy. A survey of women’s knowledge and attitudes. Arch Intern Med 1989; 149: 133–6.

   OpenUrlCrossRefPubMedWeb of Science
9. ↵
   Silverman SL, Greenwald M, Klein RA, Drinkwater BL. Effect of bone density information on decisions about hormone replacement therapy: a randomized trial. Obstet Gynecol 1997; 89: 321–5.

   OpenUrlCrossRefPubMedWeb of Science
10. ↵
    McKinlay SM, Brambilla DJ, Posner JG. The normal menopause transition. Maturitas 1992; 14: 103–15.

    OpenUrlCrossRefPubMedWeb of Science
11. ↵
    Mowen JC. The 3M model of motivation and personality: theory and empirical applications to consumer behavior. Norwell, Mass: Kluwer Academic Publishers, 1999: 314.
12. ↵
    Wallston BS, Wallston KA, Kaplan GD, Maides SA. Development and validation of the health locus of control (HLC) scale. J Consult Clin Psychol 1976; 44: 580–5.

    OpenUrlCrossRefPubMedWeb of Science
13. ↵
    Lessler JT, Sirken MG. Laboratory-based research on the cognitive aspects of survey methodology: the goals and methods of the National Center for Health Statistics study. Milbank Mem Fund Q Health Soc 1985; 63: 565–81.

    OpenUrlPubMed
14. ↵
    Fleiss JL. Statistical methods for rates and proportions. 2nd ed. New York: John Wiley & Sons, 1981.
15. ↵
    Pilote L, Hlatky MA. Attitudes of women toward hormone therapy and prevention of heart disease. Am Heart J 1995; 129: 1237–8.

    OpenUrlCrossRefPubMedWeb of Science
16. ↵
    Myths and misperceptions about aging and women’s health. Washington, DC: National Council on Aging, 1997.
17. ↵
    Griffiths F. Women’s health concerns. Is the promotion of hormone replacement therapy for prevention important to women? Fam Pract 1995; 12: 54–9.

    OpenUrlAbstract/FREE Full Text
18. ↵
    Hochbaum GM. Public participation in medical screening programs: a sociopsychological study. Washington, DC: Government Printing Office, 1958. [PHS publication no. 572.]
19. ↵
    Bandura A. Self-efficacy: toward a unifying theory of behavioral change. Psychol Rev 1977; 84: 191–215.

    OpenUrlCrossRefPubMedWeb of Science
20. ↵
    Svenson O, Rayo AO, Andersen M, Sandberg A, Svahlin I. Post-decision consolidation, as a function of the instructions to the decision maker and of the decision problem. Acta Psychol (Amst) 1994; 87: 181–97.

    OpenUrlCrossRefPubMedWeb of Science
21. ↵
    Oddens BJ, Boulet MJ. Hormone replacement therapy among Danish women aged 45–65 years: prevalence, determinants, and compliance. Obstet Gynecol 1997; 90: 269–77.

    OpenUrlCrossRefPubMedWeb of Science
22. ↵
    Larcos G. What factors influence general practitioners’ commencement of hormone replacement in perimenopausal women? Br J Clin Pract 1996; 50: 6–8.

    OpenUrlPubMed
23. ↵
    Rozenberg S, Kroll M, Vandromme J, Paesmans M, Lefever A, Ham H. Factors influencing the prescription of hormone replacement therapy. Obstet Gynecol 1997; 90: 387–91.

    OpenUrlPubMed
24. ↵
    Stanton NA, Pinto M. Behavioural compensation by drivers of a simulator when using a vision enhancement system. Ergonomics 2000; 43: 1359–70.

    OpenUrlPubMed
25. ↵
    Mosca L, Jones WK, King KB, Ouyang P, Redberg RF, Hill MN. Awareness, perception, and knowledge of heart disease risk and prevention among women in the United States. American Heart Association Women’s Heart Disease and Stroke Campaign Task Force. Arch Fam Med 2000; 9: 506–15.

    OpenUrlCrossRefPubMedWeb of Science
26. ↵
    Woloshin S, Schwartz LM, Black WC, Welch HG. Women’s perceptions of breast cancer risk: how you ask matters. Med Decis Making 1999; 19: 221–9.

    OpenUrlAbstract/FREE Full Text
27. ↵
    Braddock CH 3rd, Fihn SD, Levinson W, Jonsen AR, Pearlman RA. How doctors and patients discuss routine clinical decisions. Informed decision making in the outpatient setting. J Gen Intern Med 1997; 12: 339–45.

    OpenUrlCrossRefPubMedWeb of Science
28. ↵
    Herrington DM, Reboussin DM, Brosnihan KB, et al. Effects of estrogen replacement on the progression of coronary-artery atherosclerosis. N Engl J Med 2000; 343: 522–9.

    OpenUrlCrossRefPubMedWeb of Science
29. Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA 1998; 280: 605–13.

    OpenUrlCrossRefPubMedWeb of Science
30. ↵
    Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. JAMA 2002; 288: 321–33.

    OpenUrlCrossRefPubMedWeb of Science
31. Ross RK, Paganini-Hill A, Wan PC, Pike MC. Effect of hormone replacement therapy on breast cancer risk: estrogen versus estrogen plus progestin. J Natl Cancer Inst 2000; 92: 328–32.

    OpenUrlAbstract/FREE Full Text
32. Schairer C, Lubin J, Troisi R, Sturgeon S, Brinton L, Hoover R. Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk. JAMA 2000; 283: 485–91.

    OpenUrlCrossRefPubMedWeb of Science
33. ↵
    Pradhan AD, Manson JE, Rossouw JE, et al. Inflammatory biomarkers, hormone replacement therapy, and incident coronary heart disease: prospective analysis from the Women’s Health Initiative observational study. JAMA 2002; 288: 980–7.

    OpenUrlCrossRefPubMedWeb of Science